TNGXTango Therapeutics, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+36.1% YoY

Gross Profit

$20M100.0% margin

Operating Income

-$30M-148.7% margin

Net Income

-$26M-128.6% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+207.1%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$381M

Total Liabilities

$134M

Stockholders' Equity

$248M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$15M	+36.1%
Gross Profit	$20M	$13M	+51.8%
Operating Income	-$30M	-$23M	-27.1%
Net Income	-$26M	-$21M	-23.4%

Revenue Segments

License Revenue

$12M61%

Collaboration Revenue

$8M39%

TNGX Q2 2024 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena